| Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria CH Polman, SC Reingold, B Banwell, M Clanet, JA Cohen, M Filippi, ... Annals of neurology 69 (2), 292-302, 2011 | 11159 | 2011 |
| Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis WI McDonald, A Compston, G Edan, D Goodkin, HP Hartung, FD Lublin, ... Annals of Neurology: Official Journal of the American Neurological …, 2001 | 9413 | 2001 |
| Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria AJ Thompson, BL Banwell, F Barkhof, WM Carroll, T Coetzee, G Comi, ... The Lancet Neurology 17 (2), 162-173, 2018 | 7423 | 2018 |
| Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria” CH Polman, SC Reingold, G Edan, M Filippi, HP Hartung, L Kappos, ... Annals of Neurology: Official Journal of the American Neurological …, 2005 | 6680 | 2005 |
| Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK M Voysey, SAC Clemens, SA Madhi, LY Weckx, PM Folegatti, PK Aley, ... The Lancet 397 (10269), 99-111, 2021 | 5588 | 2021 |
| Global, regional, and national age-sex specific mortality for 264 causes of death, 1980–2016: a systematic analysis for the Global Burden of Disease Study 2016 M Naghavi, AA Abajobir, C Abbafati, KM Abbas, F Abd-Allah, SF Abera, ... The lancet 390 (10100), 1151-1210, 2017 | 5127 | 2017 |
| Defining the clinical course of multiple sclerosis: the 2013 revisions FD Lublin, SC Reingold, JA Cohen, GR Cutter, PS Sørensen, ... Neurology 83 (3), 278-286, 2014 | 3969 | 2014 |
| Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial PM Folegatti, KJ Ewer, PK Aley, B Angus, S Becker, ... The Lancet 396 (10249), 467-478, 2020 | 2884 | 2020 |
| Non-invasive mapping of connections between human thalamus and cortex using diffusion imaging TEJ Behrens, H Johansen-Berg, MW Woolrich, SM Smith, ... Nature neuroscience 6 (7), 750-757, 2003 | 2718 | 2003 |
| Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial MN Ramasamy, AM Minassian, KJ Ewer, AL Flaxman, PM Folegatti, ... The Lancet 396 (10267), 1979-1993, 2020 | 1751 | 2020 |
| Atlas of multiple sclerosis 2013: a growing global problem with widespread inequity P Browne, D Chandraratna, C Angood, H Tremlett, C Baker, BV Taylor, ... Neurology 83 (11), 1022-1024, 2014 | 1590 | 2014 |
| Development of a multiple sclerosis functional composite as a clinical trial outcome measure GR Cutter, ML Baier, RA Rudick, DL Cookfair, JS Fischer, J Petkau, ... Brain 122 (5), 871-882, 1999 | 1459 | 1999 |
| Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four … M Voysey, SAC Clemens, SA Madhi, LY Weckx, PM Folegatti, PK Aley, ... The Lancet 397 (10277), 881-891, 2021 | 1395 | 2021 |
| The multiple sclerosis impact scale (MSIS-29) a new patient-based outcome measure J Hobart, D Lamping, R Fitzpatrick, A Riazi, A Thompson Brain 124 (5), 962-973, 2001 | 1269 | 2001 |
| Neural correlates of motor recovery after stroke: a longitudinal fMRI study NS Ward, MM Brown, AJ Thompson, RSJ Frackowiak Brain 126 (11), 2476-2496, 2003 | 1244 | 2003 |
| A longitudinal study of abnormalities on MRI and disability from multiple sclerosis PA Brex, O Ciccarelli, JI O'Riordan, M Sailer, AJ Thompson, DH Miller New England Journal of Medicine 346 (3), 158-164, 2002 | 1217 | 2002 |
| Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis LK Fisniku, PA Brex, DR Altmann, KA Miszkiel, CE Benton, R Lanyon, ... Brain 131 (3), 808-817, 2008 | 1202 | 2008 |
| Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial J Zajicek, P Fox, H Sanders, D Wright, J Vickery, A Nunn, A Thompson The lancet 362 (9395), 1517-1526, 2003 | 1045 | 2003 |
| ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis X Montalban, R Gold, AJ Thompson, S Otero-Romero, MP Amato, ... Multiple Sclerosis Journal 24 (2), 96-120, 2018 | 986 | 2018 |
| Clinically isolated syndromes suggestive of multiple sclerosis, part I: natural history, pathogenesis, diagnosis, and prognosis D Miller, F Barkhof, X Montalban, A Thompson, M Filippi The Lancet Neurology 4 (5), 281-288, 2005 | 964 | 2005 |
